Literature DB >> 19352470

Accomplishments in 2007 in biologic markers for gastrointestinal cancers.

Heinz-Josef Lenz1, Patrick Johnston.   

Abstract

OverviewPrognostic or Predictive Factors K-ras and Ligands of EGFRCirculating Tumor CellsArray Signatures as Prognostic/Predictive Markers18q and MSI as Prognostic MarkersUse of Thymidylate Synthase To Assign ChemotherapyAccomplishments (or Lack of Accomplishments) Therapy Incorporation of Targeted Therapies in Colon Cancer TreatmentIncorporation of Targeted Therapies in Pancreatic Cancer TreatmentUGT1A1*28 Polymorphism and Irinotecan ToxicityBasic Science Targeting VEGFIdentification of VEGF-Independent PathwaysTargeting EGFRTargeting Other PathwaysFuture Directions Comments on ResearchFuture Challenges.

Entities:  

Year:  2008        PMID： 19352470      PMCID： PMC2664915     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


  24 in total

1.  Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study.

Authors:  George P Kim; Linda H Colangelo; H Samuel Wieand; Soonmyung Paik; Ilan R Kirsch; Norman Wolmark; Carmen J Allegra
Journal:  J Clin Oncol       Date:  2007-01-16       Impact factor: 44.544

2.  Predictive value of microsatellite instability-high remains controversial.

Authors:  George P Kim; Linda H Colangelo; Soonmyung Paik; Michael J O'Connell; Ilan R Kirsch; Carmen Allegra; Norman Wolmark
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

3.  Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.

Authors:  Sandra Van Schaeybroeck; Anthi Karaiskou-McCaul; Donal Kelly; Daniel Longley; Leeona Galligan; Eric Van Cutsem; Patrick Johnston
Journal:  Clin Cancer Res       Date:  2005-10-15       Impact factor: 12.531

4.  Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells.

Authors:  Yusuke Mizukami; Won-Seok Jo; Eva-Maria Duerr; Manish Gala; Jingnan Li; Xiaobo Zhang; Michael A Zimmer; Othon Iliopoulos; Lawrence R Zukerberg; Yutaka Kohgo; Maureen P Lynch; Bo R Rueda; Daniel C Chung
Journal:  Nat Med       Date:  2005-08-28       Impact factor: 53.440

5.  PIK3CA mutation is predictive of poor survival in patients with colorectal cancer.

Authors:  Shunsuke Kato; Satoru Iida; Tetsuro Higuchi; Toshiaki Ishikawa; Yoko Takagi; Masamichi Yasuno; Masayuki Enomoto; Hiroyuki Uetake; Kenichi Sugihara
Journal:  Int J Cancer       Date:  2007-10-15       Impact factor: 7.396

6.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

7.  Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.

Authors:  Henry Q Xiong; Arthur Rosenberg; Albert LoBuglio; William Schmidt; Robert A Wolff; John Deutsch; Michael Needle; James L Abbruzzese
Journal:  J Clin Oncol       Date:  2004-07-01       Impact factor: 44.544

8.  Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

Authors:  Shirin Khambata-Ford; Christopher R Garrett; Neal J Meropol; Mark Basik; Christopher T Harbison; Shujian Wu; Tai W Wong; Xin Huang; Chris H Takimoto; Andrew K Godwin; Benjamin R Tan; Smitha S Krishnamurthi; Howard A Burris; Elizabeth A Poplin; Manuel Hidalgo; Jose Baselga; Edwin A Clark; David J Mauro
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544

Review 9.  The impact of expression profiling on prognostic and predictive testing in breast cancer.

Authors:  J S Reis-Filho; C Westbury; J-Y Pierga
Journal:  J Clin Pathol       Date:  2006-03       Impact factor: 3.411

10.  Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.

Authors:  F Di Fiore; F Blanchard; F Charbonnier; F Le Pessot; A Lamy; M P Galais; L Bastit; A Killian; R Sesboüé; J J Tuech; A M Queuniet; B Paillot; J C Sabourin; F Michot; P Michel; T Frebourg
Journal:  Br J Cancer       Date:  2007-03-20       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.